[1] Shaw A T, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer[J]. Clinical Cancer Research, 2011, 17(8):2081-2086
[2] Ou S,Bartlett C,Mino-Kenudson M,et al. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer:A success story to usher in the second decade of molecular targeted therapy in oncology[J]. Oncologist,2012,17(11):1351-1375
[3] Choi Y,Takeuchi K,Soda M,et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer[J]. Cancer Res,2008,68(13):4971-4976
[4] Li Y,Ye X,Liu J,et al. Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors[J]. Neoplasia,2011,13(1):1-11
[5] 葛丹丹, 宫平. 色瑞替尼(ceritinib)[J]. 中国药物化学杂志, 2014, (5):420-420 Ge Dandan, Gong Ping. Ceritinib[J]. China Magazine Pharmaceutical Chemistry, 2014, (5):420-420(in chinese)
[6] Shaw A T, Kim D W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J]. New England Journal of Medicine, 2013, 368(25):2385-2394
[7] Ettinger D,Akerley W,Borghaei H,et al. Non-Small cell lung cancer,version 2. 2013[J]. J Natl Compr Canc Netw, 2013, 11(6):645-653
[8] Stockwell S. FDA approval for zykadia for late-stage lung cancer[J]. Oncology Times, 2014, 36:10
[9] 陈少波, 张厚德. 克唑替尼抗肿瘤的研究进展[J]. 中国现代医生, 2015, (14):156-160 Chen Shaobo, Zhang Houde. Research progress of anti tumor of Crizotinib[J]. Chinese Modern Doctor, 2015, (14):156-160(in chinese)
[10] McDermott U,Iafrate A,Gray N,et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors[J]. Cancer Res, 2008, 68(9):3389-3395
[11] Chen J,Jiang C,Wang S. LDK378:A promising anaplastic lymphoma kinase (ALK) inhibitor[J]. J Med Chem, 2013, 56(14):5673-5674
[12] Galkin A, Melnick J, Kim S, et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK[J]. Proceedings of the National Academy of Sciences, 2007, 104(1):270-275
[13] Garcia-Echeverria C, Kanazawa T, Kawahara E, et al. 2,4-Di(phenylamino)pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders:WO, 2004080980[P]. 2004-09-23
[14] Kwiatkowski N, Jelluma N, Filippakopoulos P, et al. Small-Molecule kinase inhibitors provide insight into Mps1 cell cycle function[J]. Nature Chemical Biology, 2010, 6(5):359-368
[15] Gray N, Zhou W. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith:US, 12/976,980[P]. 2010-12-22
[16] Marsilje T, Pei W, Chen B, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N 2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl) phenyl)-N 4-(2-(isopropylsulfonyl) phenyl) pyrimidine-2, 4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials[J]. Journal of Medicinal Chemistry, 2013, 56(14):5675-5690
[17] 王永珍, 赵砚瑾, 胡文祥, 等. 2,5-二氯-N-[2-(异丙基磺酰基)苯]-4-胺的合成[J]. 昆明理工大学学报,2012, 37:300-304 Wang Yongzhen, Zhao Yanjin, Hu Wenxiang, et al. Synthesis of 2,5-dichloro-N-[2-(isopropylsulfonyl) phenyl]-pyrimidin-4-amine[J]. Journal of Kunming University of Science and Technology, 2012, 37:300-304(in Chinese)
[18] 邓维, 刘磊, 郭庆祥. 铜催化交叉偶联反应研究的新进展[J]. 有机化学, 2004, 24(2):150-165 Deng Wei, Liu Lei, Guo Qingxiang. Recent progress in copper-catalyzed cross-coupling reactions[J]. Chinese Journal of Organic Chemistry, 2004, 24(2):150-165(in Chinese)
|
2018, Vol. 35 
